PubMed Health⌕ Search

Biomedical subjects

E Berglin

Publications and source records attributed to E Berglin.

67 records · Page 4Linked to original sources
PubMed1979

Plasma administration to defibrinogenated dogs during extracorporeal circulation.

Plasma, in an amount corresponding to 0.05 gm fibrinogen/Kg of body weight, was administered during one hour to defibrinogenated dogs subjected to extracorporeal circulation. Four blood filters included in the extracorporeal circuit were removed one by one at 30-minute intervals. The prefilter pressures rose gradually during the whole experiment. Scanning electron microscopy of the filter surface revealed equal amounts of deposits before, during and after the infusion of plasma. Only minimal amounts of fibrin were found on the filter surfaces by immunoelectrophoresis. Mean arterial pressure, arterial blood gases, fibrinogen concentration, platelet count and leukocyte count were followed before, during and after plasma infusion and showed no significant changes. Thus, it is possible to administer limited amounts of plasma to defibrinogenated dogs subjected to extracorporeal circulation.

Animals↗
PubMed1977

Mediastinoscopy in cancer of the oesophagus or cardia.

Fifty consecutive patients with verified squamous cell carcinoma in the oesophagus or adenocarcinoma had mediastinal metastases. One of 21 patients scopy. Seven of 29 patients with squamous cell carcinoma and mediastinal metastases. One of 21 patients with adenocarcinoma had this finding. It is concluded that patients with squamous cell carcinoma of the oesophagus should be mediastinoscopied and that it is also a worthwhile method in patients with adenocarcinoma.

Adenocarcinoma↗
PubMed1976

Anticoagulation with defibrase during prolonged extracorporeal circulation in the dog.

Defĩbrase was used for anticoagulation in dogs during extracorporeal perfusion up to 6 hours with a Travenol membrane oxygenator or a Pall filter. The anticoagulation effect was adequate. The already low fibrinogen concentration became unmeasurable, the platelet count decreased, and the fibrin(ogen) degradation products increased during the perfusion. Histological examination showed platelets and white blood cells on the membranes. Perfusion pressure and blood flow were stable during the experiments, and no bleeding, thromboembolism or other adverse side-effects were noted. Defibrase might be an alternative to heparin for anticoagulation during extra-corporeal circulation.

Animals↗
PubMedDate not supplied

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.

OBJECTIVES: To analyse the effects of infliximab infusions on serum levels of lipids in patients with rheumatoid arthritis (RA) treated for 2 years. METHODS: Fifty-two patients (41 females and 11 males) with RA undergoing infliximab treatment (3 mg/kg) were consecutively recruited into the study. The mean (+/-SD) age of the patients was 54.6+/-12.5 years and mean disease duration was 14.1+/-8.6 years. Blood was sampled before infusion at baseline, and at 3, 6, 12, 18 and 24 months. Forty-one of the patients were also treated with methotrexate, 13 with other disease-modifying anti-rheumatic drugs (DMARDs) and 28 with prednisolone (<10 mg daily). For comparison, lipid levels were followed for 2 years in 70 consecutively included patients with early RA during treatment with conventional DMARDs. RESULTS: There was an initial increase in plasma levels of cholesterol, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, and LDL/HDL and total/HDL cholesterol ratios. However, after 3 months HDL-cholesterol decreased significantly, followed after 6 months by cholesterol and LDL-cholesterol. The LDL/HDL and total/HDL-cholesterol ratios remained significantly raised. HDL-cholesterol increased and the ratios improved in patients with early RA receiving conventional treatment. The changes over time differed significantly between the patient groups. CONCLUSION: During infliximab infusion a pro-atherogenic lipid profile developed despite reduced inflammatory activity. The long-term decrease in HDL-cholesterol was unexpected considering the known effects of tumour necrosis factor-alpha (TNFalpha).

Antibodies, Monoclonal↗
PubMedDate not supplied

Glucose and insulin infusion directly after cardiac surgery: effects on systemic glucose uptake, catecholamine excretion, O2 consumption, and CO2 production.

Systemic glucose uptake was studied in 31 patients during 4 hr starting 1 hr after open heart surgery, using the hyperinsulinemic "clamp" technique at different plasma insulin levels and at a glucose concentration of 6 or 10 mmol/liter. Possible metabolic side effects related to the glucose uptake were studied by measurements of urinary catecholamine excretion, O2 consumption, CO2 production, and arterial PCO2. A peak systemic glucose uptake of 7.0 +/- 0.4 mg/kg body weight/min was found at a plasma insulin concentration of 3192 +/- 150 mU/liter and a blood glucose concentration of 10.2 +/- 0.1 mmol/liter. No significant difference was found in urinary catecholamine excretion compared to control patients. O2 consumption was unaltered while a 15% increase in CO2 production was observed.

Adult↗
PubMedDate not supplied

Splanchnic glucose balance and insulin resistance in the early postoperative phase of cardiac surgery.

The splanchnic balance of glucose was studied in the basal state and at three levels of "clamped" hyperinsulinemia (260 +/- 23, 510 +/- 59, 3875 +/- 367 mU/liter) in 24 patients (43-70 years of age), who had undergone coronary surgery about 1 hr previously. The splanchnic balance of glucose in the basal state was negative in all patients (-1.6 +/- 0.3 mg/kg/min) and was changed into a zero-balance within 30 min when 0.15 or 0.3 U/kg/hr of insulin was infused. At an insulin infusion rate of 1.0 U/kg/hr the net splanchnic glucose balance was turned into a significant positive balance of an average 0.9 +/- 0.3 mg/kg/min.

Adult↗
PubMedDate not supplied

Assessment of myocardial damage by circulating cardiac myosin light chain I after heart transplantation.

The purpose of this study was to evaluate the cardiac damage by cardiac myosin light chain I after transplantation. This study included 30 patients who underwent cardiac operations and who were divided into three groups. These groups consisted of (1) control group, 15 valvular patients without coronary disease (no electrocardiography changes and creatine kinase MB isoenzyme of 100 micrograms/L or less); (2) infarction group, eight patients (six coronary bypass and two valvular patients with perioperative infarction pattern in the electrocardiography and creatine kinase MB isoenzyme of 100 micrograms/L or more; and (3) transplantation group, seven transplant patients (six heart and one heart-lung). The peak cardiac myosin light chain I value in the transplantation group (32.9 +/- 3.4 micrograms/L) was comparable to the infarction group (27.6 +/- 2.6 micrograms/L), and both of them were significantly higher than the control group (9.2 +/- 0.9 micrograms/L) (p < 0.01). Peak cardiac myosin light chain I levels in the control and transplantation groups correlated with the ischemic time (r = 0.48, p < 0.05 and r = 0.67, p < 0.05, respectively). The total dose of dopamine in the transplantation group correlated with the peak cardiac myosin light chain I (r = 0.67, p < 0.05), and with the cardiac myosin light chain I value on day 7 (r = 0.88, p < 0.01). This study suggests that circulating cardiac myosin light chain I estimations are useful to evaluate myocardial damage after transplantation during postoperative week 1.

Aged↗